Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 3Phase 4 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 3Non-Squamous Non-Small Cell Lung Cancer 2Pancreatic Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Renal Cell 1Adenocarcinoma of Lung 1

Interventions

Sunitinib 5Everolimus 5Nivolumab 4pazopanib 3cabozantinib 2aldesleukin 2palbociclib 1olaparib 1lenvatinib 1Zoledronic Acid 1Tobacco Use Cessation Devices 1Standard of Care 1Specimen Handling 1Sorafenib 1Single Person 1Radiotherapy 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1Nutrition Therapy 1Midazolam 1Ipilimumab 1Interferons 1Immune Checkpoint Inhibitors 1High-Energy Shock Waves 1Gene Expression Profiling 1Gemcitabine 1Erlotinib Hydrochloride 1Early Intervention, Educational 1Counseling 1Caffeine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Carcinoma, Renal Cell × Erlotinib Hydrochloride × Clear all
NCT01402089 2016-02-02

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Cantonal Hospital of St. Gallen

Phase 4 Completed
54 enrolled
GastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡